The University of Southampton
University of Southampton Institutional Repository

Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom

Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom
Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom
Purpose: To evaluate acute toxicity induced by chemotherapy for breast cancer in a retrospective study of 62 BRCA1/2 mutation carriers matched 1:1 with women who had treatment for sporadic disease in the United Kingdom between 1983 and 2003. Experimental Design: All participants were interviewed by one of two researchers using Standardized questionnaires, and their medical records were reviewed by one research nurse. The two main regimens received were cyclophosphamide, methotrexate, and fluorouracil and fluorouracil, epirubicin, and cyclophosphamide. The proportion of cases and controls receiving anthracycline-based treatment was equivalent; but fewer BRCA1 cases received this treatment than did BRCA2 mutation carriers. Toxicity was documented using the Eastern Cooperative Oncology Group Common Toxicity Criteria for hematologic, infective, and gastrointestinal toxicities. No increase in toxicity was seen in BRCA1/2 mutation carriers. Results: The only significant difference was that neutropenia was less evident in BRCA2 mutation carriers than in either BRCA1 mutation carriers or controls. As a result, there was no requirement for dose reduction among BRCA2 mutation carriers, in contrast to 10 of 39 BRCA1 carriers and 16 of 62 controls (P = 0.02). Conclusions: This result has implications for therapy and indicates that women with mutations in BRCA1 and BRCA2 may be given the same doses of chemotherapy as noncarriers
brca2, breast cancer, oncology-group, disease, chemotherapy, brca1, DNA-repair, mutations, cancer, 2, cells, breast-cancer, carcinoma, breast, mutation, women
1078-0432
7033-7038
Shanley, Susan
a0d8bf7d-730c-40ad-b9d0-d6e85f87fb95
McReynolds, Kate
e1d58175-f4e8-42b8-9f46-d4adaddd0e39
Rdern-Jones, Audrey
bf4f791b-5d83-4fed-80ca-9f35b42eeda4
Ahern, Roger
8bfa32f2-387a-44e1-aa0b-f13230af79ec
Fernando, Indrajit
94b602fc-66f8-4af7-b795-0bf7cf772c80
Yarnold, John
16e929ca-7e4b-41b4-967c-2ead0e634ca1
Evans, Gareth
ee001bc1-9b29-4a58-a251-a27b18eff669
Eccles, Diana
5b59bc73-11c9-4cf0-a9d5-7a8e523eee23
Hodgson, Shirley
a9f6b2c4-f329-40b5-8b07-a74b3fdd1a0c
Ashley, Sue
5c221302-f578-4e3e-821e-ea1132fdd278
Ashcroft, Linda
701684fa-f410-4b20-a500-81e785063514
Tutt, Andrew
1b02babf-5752-464e-bd87-665a7880c591
Bancroft, Elizabeth
3b9eca84-7e95-4db7-b68f-43a69d70c3b6
Short, Susan
fc376115-7ea0-42df-af77-28630a39323c
Smith, Ian
e28e3644-e801-4ca9-9449-16a559e66f03
Gui, Gerald
c3a0464e-7ab7-40fe-925a-c35803b22a5c
Barr, Lester
1c19e12a-2e80-40ae-9e54-3f97ea75669d
Baildam, Andrew
4d612289-1e41-47af-b447-71ba435ef852
Howell, Anthony
1a0a7e78-3d51-4e76-8cd5-bd46cb90d588
Royle, Gavin
463ea7b0-3319-4117-a3fd-791427d30231
Pierce, Lori
b5d9184a-dd2b-4968-9727-fb5ebee8a249
Easton, Douglas
de2d61a0-74d3-4548-9cd8-36ea7642ff29
Eeles, Rosalind
ebf4ff74-6a85-49b7-8742-139ddd67ccb4
The Breast Unit of the Royal Marsden NHS Foundation Trust
Shanley, Susan
a0d8bf7d-730c-40ad-b9d0-d6e85f87fb95
McReynolds, Kate
e1d58175-f4e8-42b8-9f46-d4adaddd0e39
Rdern-Jones, Audrey
bf4f791b-5d83-4fed-80ca-9f35b42eeda4
Ahern, Roger
8bfa32f2-387a-44e1-aa0b-f13230af79ec
Fernando, Indrajit
94b602fc-66f8-4af7-b795-0bf7cf772c80
Yarnold, John
16e929ca-7e4b-41b4-967c-2ead0e634ca1
Evans, Gareth
ee001bc1-9b29-4a58-a251-a27b18eff669
Eccles, Diana
5b59bc73-11c9-4cf0-a9d5-7a8e523eee23
Hodgson, Shirley
a9f6b2c4-f329-40b5-8b07-a74b3fdd1a0c
Ashley, Sue
5c221302-f578-4e3e-821e-ea1132fdd278
Ashcroft, Linda
701684fa-f410-4b20-a500-81e785063514
Tutt, Andrew
1b02babf-5752-464e-bd87-665a7880c591
Bancroft, Elizabeth
3b9eca84-7e95-4db7-b68f-43a69d70c3b6
Short, Susan
fc376115-7ea0-42df-af77-28630a39323c
Smith, Ian
e28e3644-e801-4ca9-9449-16a559e66f03
Gui, Gerald
c3a0464e-7ab7-40fe-925a-c35803b22a5c
Barr, Lester
1c19e12a-2e80-40ae-9e54-3f97ea75669d
Baildam, Andrew
4d612289-1e41-47af-b447-71ba435ef852
Howell, Anthony
1a0a7e78-3d51-4e76-8cd5-bd46cb90d588
Royle, Gavin
463ea7b0-3319-4117-a3fd-791427d30231
Pierce, Lori
b5d9184a-dd2b-4968-9727-fb5ebee8a249
Easton, Douglas
de2d61a0-74d3-4548-9cd8-36ea7642ff29
Eeles, Rosalind
ebf4ff74-6a85-49b7-8742-139ddd67ccb4

Shanley, Susan, McReynolds, Kate, Rdern-Jones, Audrey, Ahern, Roger, Fernando, Indrajit, Yarnold, John, Evans, Gareth, Eccles, Diana, Hodgson, Shirley, Ashley, Sue, Ashcroft, Linda, Tutt, Andrew, Bancroft, Elizabeth, Short, Susan, Smith, Ian, Gui, Gerald, Barr, Lester, Baildam, Andrew, Howell, Anthony, Royle, Gavin, Pierce, Lori, Easton, Douglas and Eeles, Rosalind , The Breast Unit of the Royal Marsden NHS Foundation Trust (2006) Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom. Clinical Cancer Research, 12 (23), 7033-7038.

Record type: Article

Abstract

Purpose: To evaluate acute toxicity induced by chemotherapy for breast cancer in a retrospective study of 62 BRCA1/2 mutation carriers matched 1:1 with women who had treatment for sporadic disease in the United Kingdom between 1983 and 2003. Experimental Design: All participants were interviewed by one of two researchers using Standardized questionnaires, and their medical records were reviewed by one research nurse. The two main regimens received were cyclophosphamide, methotrexate, and fluorouracil and fluorouracil, epirubicin, and cyclophosphamide. The proportion of cases and controls receiving anthracycline-based treatment was equivalent; but fewer BRCA1 cases received this treatment than did BRCA2 mutation carriers. Toxicity was documented using the Eastern Cooperative Oncology Group Common Toxicity Criteria for hematologic, infective, and gastrointestinal toxicities. No increase in toxicity was seen in BRCA1/2 mutation carriers. Results: The only significant difference was that neutropenia was less evident in BRCA2 mutation carriers than in either BRCA1 mutation carriers or controls. As a result, there was no requirement for dose reduction among BRCA2 mutation carriers, in contrast to 10 of 39 BRCA1 carriers and 16 of 62 controls (P = 0.02). Conclusions: This result has implications for therapy and indicates that women with mutations in BRCA1 and BRCA2 may be given the same doses of chemotherapy as noncarriers

Full text not available from this repository.

More information

Published date: 1 December 2006
Keywords: brca2, breast cancer, oncology-group, disease, chemotherapy, brca1, DNA-repair, mutations, cancer, 2, cells, breast-cancer, carcinoma, breast, mutation, women

Identifiers

Local EPrints ID: 62925
URI: http://eprints.soton.ac.uk/id/eprint/62925
ISSN: 1078-0432
PURE UUID: bcf5ff54-5512-40d9-8925-6b4d75a684e8

Catalogue record

Date deposited: 04 Sep 2008
Last modified: 13 Mar 2019 20:26

Export record

Contributors

Author: Susan Shanley
Author: Kate McReynolds
Author: Audrey Rdern-Jones
Author: Roger Ahern
Author: Indrajit Fernando
Author: John Yarnold
Author: Gareth Evans
Author: Diana Eccles
Author: Shirley Hodgson
Author: Sue Ashley
Author: Linda Ashcroft
Author: Andrew Tutt
Author: Elizabeth Bancroft
Author: Susan Short
Author: Ian Smith
Author: Gerald Gui
Author: Lester Barr
Author: Andrew Baildam
Author: Anthony Howell
Author: Gavin Royle
Author: Lori Pierce
Author: Douglas Easton
Author: Rosalind Eeles

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×